<DOC>
	<DOCNO>NCT00012389</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know irinotecan effective without oxaliplatin treat metastatic colorectal cancer . PURPOSE : Randomized phase III trial compare effectiveness irinotecan without oxaliplatin treat patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Irinotecan With Without Oxaliplatin Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival patient metastatic colorectal cancer treat irinotecan without oxaliplatin . - Compare response rate , time tumor-related worsening symptom , time disease progression , onset duration response , duration disease stabilization patient treat regimen . - Compare safety regimens patient . OUTLINE : This randomize , open label , multicenter study . Patients stratify accord Karnofsky performance status ( 50-60 % vs 70-100 % ) , number metastatic organ involve ( 1 vs 2 ) , lactic dehydrogenase ( great 1.5 time upper limit normal ( ULN ) vs great 1.5 time ULN ) , prior fluorouracil chemotherapy ( adjuvant v first-line treatment metastatic disease ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive irinotecan IV 90 minute day 1 . - Arm II : Patients receive oxaliplatin IV 120 minute follow irinotecan IV 30 minute day 1 . Courses repeat arm every 3 week 1 year absence disease progression unacceptable toxicity . Patients follow 30 day , every 4 week 3 month , every 3 month thereafter . PROJECTED ACCRUAL : A total 596 patient ( 298 per arm ) accrue study within 18 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma colon rectum Metastatic recurrent disease amenable potentially curative treatment Progressive recurrent disease 1 , 1 , regimen fluorouracil without leucovorin calcium within 6 month adjuvant chemotherapy fluorouracil leucovorin calcium PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 50100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT/SGPT great 2 time ULN ( great 5 time ULN liver metastasis present ) Alkaline phosphatase great 2 time ULN ( great 5 time ULN liver metastasis present ) Renal : Creatinine great 1.5 time ULN Cardiovascular : No unstable angina No New York Heart Association class III IV congestive heart failure No serious cardiac arrhythmia No history cardiac toxicity fluorouracil/leucovorin calcium No myocardial infarction within past 6 month Pulmonary : No interstitial pneumonia extensive symptomatic fibrosis lung Other : No uncontrolled predisposing colonic small bowel disorder No prior chronic enteropathy , chronic diarrhea , unresolved bowel obstruction/subobstruction No diabetes No active infection No know current peripheral neuropathy No concurrent active cancer except curatively treat nonmelanoma skin cancer carcinoma situ cervix No intolerance appropriate antiemetic No history anaphylaxis potential intolerance atropine sulfate loperamide Not pregnant nursing Negative pregnancy test PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy No prior irinotecan oxaliplatin No prior chemotherapy agent except fluorouracil without leucovorin calcium firstline therapy metastatic disease adjuvant set Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy nontarget lesion allow No prior radiotherapy target lesion unless disease progression document within radiation port At least 3 week since prior radiotherapy Surgery : At least 4 week since prior major surgical procedure recover Prior surgery primary tumor metastasis allow Other : At least 30 day since prior investigational drug No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2002</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>